Susan D. Wyrick - 13 Dec 2025 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role: Acting Chief Financial Officer and Principal Accounting Officer
Signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick
Issuer symbol: SANA
Transactions as of: 13 Dec 2025
Net transactions value: -$4,557
Form type: 4
Filing time: 16 Dec 2025, 16:16:41 UTC
Previous filing: 10 Mar 2025
Next filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wyrick Susan D.	Acting Chief Financial Officer and Principal Accounting Officer	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE	/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick	16 Dec 2025	0001568605

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SANA	Common Stock	Options Exercise	$0	+3,400	+1.9%	$0.000000	181,663	13 Dec 2025	Direct
transaction	SANA	Common Stock	Tax liability	$4,557	-873	-0.48%	$5.22	180,790	15 Dec 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SANA	Restricted Stock Units	Options Exercise		-3,400	-100%		0	13 Dec 2025	Common Stock	3,400		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.
F2	The award vested as to 100% of the restricted stock units on December 13, 2025.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer